| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4004810 | American Journal of Ophthalmology | 2008 | 16 Pages |
Abstract
Through two years, ranibizumab + PDT was more effective than PDT alone and had a low rate of associated adverse events.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Andrew N. Antoszyk, Lisa Tuomi, Carol Y. Chung, Angele Singh, FOCUS Study Group FOCUS Study Group,